richard kim, md, discusses pembrolizumab as an effective agent in hcc management
Published 6 years ago • 97 plays • Length 1:14
Download video MP4
Download video MP3
Similar videos
-
1:34
richard kim, md, on the use and sequencing of tkis in hepatocellular carcinoma (hcc)
-
1:33
richard kim, md, on the combination of cabozantinib & checkpoint inhibitors to improve hcc outcomes
-
2:08
dr. finn on studies of pembrolizumab in hepatocellular carcinoma
-
1:28
richard kim, md, on the outcome on the imbrave 150 study & the possibility of new treatment standard
-
1:26
richard kim, md, offers opinion on the redos study and dose escalation of regorafenib
-
2:10
multi-focal hepatoma, or hepatocellular carcinoma, liver masses ultrasound and color doppler video
-
17:47
opening lecture: pitfalls in imaging for liver tumors
-
47:42
immune therapy in hepatocellular carcinoma
-
1:37
dr. kim on the potential of ramucirumab in advanced hcc
-
1:47
richard kim, md determines whether checkpoint inhibitors combine with regorafenib for hcc treatment
-
1:17
richard kim, md, shares how we can utilize tkis in the management of hepatocellular carcinoma
-
0:43
richard kim, md, on the role of braf mutations in treatment of cholangiocarcinoma
-
10:42
first-line atezolizumab with bevacizumab for hcc
-
2:13
richard s. finn, md, offers opinion on the role of frontline atezolizumab bevacizumab in hcc
-
1:18
andrew zhu, md, phd, on the effectiveness of pembrolizumab in hcc patients treated with sorafenib
-
4:23
about primary cancer of the liver (hcc)
-
1:16
richard kim, md, regarding targeted therapies in treatment of cholangiocarcinoma
-
15:55
improving the outcome of patients with metastatic pancreatic cancer
-
1:02:04
advances in the multidisciplinary medical management of hepatocellular carcinoma
-
4:35
richard s. finn, md, elaborates on promising developments in the second-line treatment of hcc
-
2:45
qimr berghofer clinical director elizabeth powell
-
0:47
dr. richards on parp inhibition in pancreatic cancer
Clip.africa.com - Privacy-policy